1
|
Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells. Int J Mol Sci 2019; 20:ijms20184421. [PMID: 31500399 PMCID: PMC6769516 DOI: 10.3390/ijms20184421] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Revised: 09/02/2019] [Accepted: 09/05/2019] [Indexed: 12/30/2022] Open
Abstract
The wide range of cellular target reactions (e.g., antitumor) of gonadotropin-releasing hormone (GnRH) variants provides the possibility to develop multifunctional GnRH conjugates. The aim of our work was to compare the cytotoxic/apoptotic activity of different GnRH-based, daunorubicin (Dau)-linked conjugates with or without butyrated Lys in position 4 (4Lys(Bu)) at a molecular level in a human colorectal carcinoma cell line. Cell viability was measured by impedimetry, cellular uptake and apoptosis were studied by flow cytometry, and the expression of apoptosis-related genes was analyzed by qRT-PCR. The modification with 4Lys(Bu) resulted in an increased cytotoxic and apoptotic effects and cellular uptake of the GnRH-I and GnRH-III conjugates. Depending on the GnRH isoform and the presence of 4Lys(Bu), the conjugates could regulate the expression of several apoptosis-related genes, especially tumor necrosis factor (TNF), tumor protein p53 (TP53) and the members of growth-factor signaling. The stronger cytotoxicity of GnRH-I and GnRH-III conjugates containing 4Lys(Bu) was associated with a stronger inhibitory effect on the expression of growth-factor signaling elements in comparison with their 4Ser counterparts, in which the upregulation of TP53 and caspases (e.g., CASP9) seemed to play a more important role. We were able to provide further evidence that targeting the GnRH receptor could serve as a successful therapeutic approach in colon cancer, and GnRH-III-[4Lys(Bu),8Lys(Dau=Aoa)] proved to be the best candidate for this purpose.
Collapse
|
2
|
Yuan M, Qiu Y, Zhang L, Gao H, He Q. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma. Drug Deliv 2015; 23:1171-83. [PMID: 26036724 DOI: 10.3109/10717544.2015.1040527] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The purpose of this study was to develop an efficient dual-ligand based liposomal drug delivery system with targeting specificity as well as properties that would kill melanoma cells. Liposomes modified with transferrin (Tf) and cell-penetrating peptide TAT was prepared, which encapsulated two kinds of chemotherapy drugs, paclitaxel and doxorubicin (Tf/TAT-PTX/DOX-LP). The Tf ligands specifically bind to the overexpressed Tf receptors on the surface of melanoma cells, while the TAT ligands functioned as a classical cell penetrating peptide, helping dual-ligand liposomes be internalized by melanoma cells. The effect of dual-targeting system and "double-drug" combination therapy were evaluated both in vitro and in vivo. In vitro, cellular uptake, intracellular distribution and tumor spheroids penetration studies demonstrated that the system could not only be selectively and efficiently penetrate melanoma cells. Besides, apoptosis staining assay and cytotoxicity showed effective anti-tumor capability and obvious synergistic effect of combination therapy of PTX and DOX. In vivo imaging and fluorescent images of tumor section further demonstrated that Tf/TAT-PTX/DOX-LP had the highest tumor distribution. The results of these experiments demonstrated that double-drug liposomal drug delivery systems (DDS) had both enhanced targeting efficiency and increased therapeutic efficacy.
Collapse
Affiliation(s)
- Mingqing Yuan
- a Key Laboratory of Drug Targeting and Drug Delivery Systems , Ministry of Education, West China School of Pharmacy, Sichuan University , Chengdu , P. R. China and
| | - Yue Qiu
- a Key Laboratory of Drug Targeting and Drug Delivery Systems , Ministry of Education, West China School of Pharmacy, Sichuan University , Chengdu , P. R. China and
| | - Li Zhang
- b Elderly Digestive Department , Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences , Chengdu , China
| | - Huile Gao
- a Key Laboratory of Drug Targeting and Drug Delivery Systems , Ministry of Education, West China School of Pharmacy, Sichuan University , Chengdu , P. R. China and
| | - Qin He
- a Key Laboratory of Drug Targeting and Drug Delivery Systems , Ministry of Education, West China School of Pharmacy, Sichuan University , Chengdu , P. R. China and
| |
Collapse
|
3
|
Gao F, Li L, Fu C, Nie L, Chen D, Tang F. LHRH-PE40 fusion protein tethered silica nanorattles for imaging-guided tumor-specific drug delivery and bimodal therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2013; 25:5508-5513. [PMID: 23878059 DOI: 10.1002/adma.201301217] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2013] [Revised: 04/29/2013] [Indexed: 06/02/2023]
Abstract
Docyanine green (ICG) and LHRH-PE40 fusion protein are tethered onto drug carriers of silica nanorattles for imaging-guided tumor-specific drug delivery and bimodal therapy. The synergistic therapeutic effect of toxin PE40 and the chemotherapeutic drug docetaxel (Dtxl), specifically directed by LHRH to cancer, improves cancer treatment. Simultaneously, ICG enables real-time monitoring of the silica nanocomposites and therapeutic response.
Collapse
Affiliation(s)
- Fuping Gao
- Laboratory of Controllable Preparation and Application of Nanomaterials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China
| | | | | | | | | | | |
Collapse
|
4
|
Venetikou MS, Meleagros L, Ghatei MA, Bloom SR. Pituitary protein 7B2 plasma levels in patients with liver disease: Comparisons with other hormones and neuropeptides. Oncol Lett 2013; 6:499-506. [PMID: 24137355 PMCID: PMC3789099 DOI: 10.3892/ol.2013.1384] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Accepted: 04/30/2013] [Indexed: 11/29/2022] Open
Abstract
7B2, a protein initially isolated from the porcine pituitary gland, has been identified in numerous animal and human tissues, with the highest concentrations in the pituitary and hypothalamus. The 7B2 molecule is highly evolutionarily conserved and is considered to be indispensable in the function and regulation of proprotein convertase 2 (PC2). In the present study, the plasma 7B2 immunoreactivity (7B2-IR) of 18 patients with liver disease was studied. Of these patients, seven (three male and four female), aged 37–67 [54.6±13.5 (SD)] years, suffered from liver cirrhosis of cryptogenic (n=2) or alcoholic (n=5) aetiology. The remaining 11 patients (four male and seven female), aged 22–76 [56.1±17.6 (SD)] years, suffered from miscellaneous liver abnormalities. The clinical diagnosis was confirmed in the majority of patients by the histological examination of a percutaneous liver biopsy or by appropriate radiological investigations. Plasma bilirubin, alkaline phosphatase, aspartate aminotransferase, albumin, prothrombin time, electrolytes, urea and creatinine were measured. The plasma 7B2-IR levels were estimated using a sensitive radioimmunoassay (RIA), and the elution position of 7B2-IR was verified by gel chromatography. The mean plasma 7B2-IR concentration in patients with liver disease was 99.44±15.9 pmol/l. In the patients with hepatocellular damage due to metastatic tumours [Ca bronchus, carcinoid (n=6)], the 7B2-IR concentrations were significantly higher [185±36.9 pmol/l, (P<0.05)] compared with the overall subjects with liver damage. The results of the present study demonstrate that 7B2-IR is increased in liver disease, with the highest levels detected in patients with tumourous liver conditions.
Collapse
Affiliation(s)
- Maria S Venetikou
- Department of Medical Sciences, Faculty of Health and Caring Professions, Technological Educational Institute (TEI), Athens, Greece
| | | | | | | |
Collapse
|
5
|
Glantz Y, Sabag O, Lichtenstein M, Grodzovski I, Lorberboum-Galski H. Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein. Biotechnol Prog 2012; 28:573-80. [PMID: 22275241 DOI: 10.1002/btpr.1515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2011] [Revised: 12/06/2011] [Indexed: 11/06/2022]
Abstract
Designing a chimeric protein and developing a procedure for its stable production as a biologically active protein, are key steps in its potential application to clinical trails. IL2-Caspase3 chimeric protein designed to target activated T lymphocytes was found to be a promising molecule for targeted treatment, however was found to be difficult to produce as a biological active molecule. Thus, we designed a new version of the molecule, IL2-Caspase3s, in which six amino acids (aa 29-34) from the N-terminus of the large subunit of caspase 3 were excluded. Repeated expressions, productions, and partial purifications of the IL2-Caspase3s yielded reproducible batches with consistent results. We found that IL2-Caspase3s causes cell death in a specific, dose-, and time-dependent manner. Cell death due to IL2-Caspase3s is caused by apoptosis. This improved and biologically stable IL2-Caspase3s chimeric protein may be developed in the future for clinical trails as a promising therapy for several pathologies involving activated T-cells. Moreover, this truncated caspase 3 sequence, lacking the N-terminal six amino acids of its large subunit, may be used in other caspase 3-based chimeric proteins targeted against various human diseases, using the appropriate targeting moiety.
Collapse
Affiliation(s)
- Yitav Glantz
- Dept. of Biochemistry and Molecular Biology, IMRIC, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel
| | | | | | | | | |
Collapse
|
6
|
Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 2011; 8:605-21. [PMID: 21453191 DOI: 10.1517/17425247.2011.566269] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
INTRODUCTION The development of specific immunosuppressive reagents remains the major goal in the treatment of human diseases. One such approach is the use of recombinant immunotoxins/chimeric proteins, composed of targeting and killing moieties, fused at the cDNA level. Most of these 'magic bullets' use bacterial or plant toxins to induce cell death. These toxins are extremely potent, but they also cause severe toxicity and systemic side effects that limit the maximal doses given to patients. Moreover, being of non-human origin, they are highly immunogenic, and the resulting neutralizing antibody production impairs their efficacy. AREAS COVERED This review describes recombinant immunotoxins/chimeric proteins composed of the classical delivering, cell-targeting molecules, fused to highly cytotoxic human proteins capable of generating an intense apoptotic response within the target cell. This review focuses on the new 'Human Killing Moieties' of these targeted proteins and describes recent progress in the development of these promising molecules. EXPERT OPINION Human toxin-based immunotoxins/chimeric proteins for the targeted delivery of drugs are still in their early stages of development. However, they are certain to advance in the very near future to become an extra weapon in the everlasting war against human diseases, mainly cancer.
Collapse
Affiliation(s)
- Haya Lorberboum-Galski
- The Hebrew University, Institute for Medical Research - Israel-Canada, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Jerusalem 91120, Israel.
| |
Collapse
|
7
|
Abstract
Targeted drug delivery to specific group of cells offers an attractive strategy to minimize the undesirable side effects and achieve the therapeutic effect with a lower dose. Both linear and cyclic peptides have been explored as trafficking moiety due to ease of synthesis, structural simplicity, and low probability of undesirable immunogenicity. Peptides derived from sequence of cell surface proteins, such as intercellular adhesion molecule-1 (ICAM-1), LHRH, Bombesin, and LFA-1, have shown potent binding affinity to the target cell surface receptors. Moreover, peptides derived from ICAM-1 receptor can be internalized by the leukemic T-cells along with the conjugated moiety offering the promise to selectively treat cancers and autoimmune diseases. Systematic analyses have revealed that physicochemical properties of the drug-peptide conjugates and their mechanism of receptor-mediated cellular internalization are important controlling factors for developing a successful targeting system. This review is focused on understanding the factors involved in the development of an effective drug-peptide conjugate with an emphasis on the chemistry and biology of the conjugates. Reported results on several promising drug-peptide conjugates have been critically evaluated. The approaches and results presented here will serve as a guide to systematically approach targeted delivery of cytotoxic drug molecules using peptides for treatment of several diseases.
Collapse
Affiliation(s)
- Sumit Majumdar
- Department of Pharmaceutical Chemistry, The University of Kansas, Simons Research Laboratories, 2095 Constant Ave., Lawrence, Kansas, 66047, USA
| | | |
Collapse
|
8
|
Vlashi E, Sturgis JE, Thomas M, Low PS. Real Time, Noninvasive Imaging and Quantitation of the Accumulation of Ligand-Targeted Drugs into Receptor-Expressing Solid Tumors. Mol Pharm 2009; 6:1868-75. [PMID: 19754150 DOI: 10.1021/mp900158d] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Erina Vlashi
- Department of Chemistry and Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907
| | - Jennifer E. Sturgis
- Department of Chemistry and Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907
| | - Mini Thomas
- Department of Chemistry and Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907
| | - Philip S. Low
- Department of Chemistry and Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907
| |
Collapse
|
9
|
Di Cristina M, Minenkova O, Pavoni E, Beghetto E, Spadoni A, Felici F, Gargano N. A novel approach for identification of tumor-associated antigens expressed on the surface of tumor cells. Int J Cancer 2007; 120:1293-303. [PMID: 17163417 DOI: 10.1002/ijc.22395] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
To improve tumor targeting in a subset of patients, where tumor cells do not express the well-known tumor antigens widely used in immunotherapy, we have developed a novel biotechnological tool. It is useful for tumors of various origins for the identification of tumor-associated proteins, which are differentially expressed in tumor cells with respect to normal tissue, and exposed on the cell surface. For this purpose, a combination of techniques, such as "suppression subtractive hybridization" and "transmembrane trapping," was employed. In applying this novel approach to breast cancer, we identified a large panel of cDNA fragments encoding for the well-known tumor-associated surface antigens, such as erb-B2, erbB3 and the urokinase receptor and, more importantly, for several clones overexpressed in breast cancer, whose cDNA fragments match the sequences of hypothetical transmembrane proteins with unknown function. The latter may represent novel tumor-specific targets.
Collapse
Affiliation(s)
- Manlio Di Cristina
- Kenton Laboratories, Via Pontina Km. 30.400, 00040 Pomezia (Rome), Italy
| | | | | | | | | | | | | |
Collapse
|